| Primary |
| Prophylaxis |
36.7% |
| Acute Myeloid Leukaemia |
33.2% |
| Acute Myeloid Leukaemia Recurrent |
18.2% |
| Myelodysplastic Syndrome |
2.0% |
| Pneumonia |
1.3% |
| Sepsis |
0.9% |
| Acute Leukaemia |
0.8% |
| Constipation |
0.8% |
| Insomnia |
0.7% |
| Diabetes Mellitus |
0.7% |
| Pyrexia |
0.7% |
| Acute Promyelocytic Leukaemia |
0.6% |
| Hypertension |
0.6% |
| Bacterial Infection |
0.5% |
| Pain |
0.5% |
| Sinusitis |
0.5% |
| Graft Versus Host Disease |
0.4% |
| Infection |
0.3% |
| Hyperlipidaemia |
0.3% |
| Neutrophil Count Decreased |
0.3% |
|
| White Blood Cell Count Decreased |
29.4% |
| Weight Increased |
12.1% |
| Sepsis |
10.7% |
| Venoocclusive Liver Disease |
10.3% |
| Pyrexia |
7.4% |
| Thrombocytopenia |
5.0% |
| Platelet Count Decreased |
3.9% |
| Pneumonia |
3.4% |
| Vomiting |
3.1% |
| White Blood Cell Count Increased |
2.1% |
| Febrile Neutropenia |
1.6% |
| Infusion Related Reaction |
1.6% |
| Tachycardia |
1.6% |
| Ventricular Tachycardia |
1.4% |
| Septic Shock |
1.3% |
| Multi-organ Failure |
1.0% |
| Oedema |
1.0% |
| Pancytopenia |
1.0% |
| Pulmonary Oedema |
1.0% |
| Renal Failure |
1.0% |
|
| Secondary |
| Prophylaxis |
33.0% |
| Acute Myeloid Leukaemia |
27.6% |
| Acute Myeloid Leukaemia Recurrent |
12.1% |
| Product Used For Unknown Indication |
6.8% |
| Drug Use For Unknown Indication |
4.3% |
| Myelodysplastic Syndrome |
3.2% |
| Acute Leukaemia |
2.0% |
| Pyrexia |
2.0% |
| Pain |
1.1% |
| Constipation |
1.0% |
| Leukaemia |
1.0% |
| Acute Promyelocytic Leukaemia |
0.8% |
| Antifungal Prophylaxis |
0.8% |
| Pneumonia |
0.8% |
| Diabetes Mellitus |
0.7% |
| Immunosuppressant Drug Therapy |
0.7% |
| Nausea |
0.7% |
| Insomnia |
0.5% |
| Diarrhoea |
0.4% |
| Premedication |
0.4% |
|
| White Blood Cell Count Decreased |
21.0% |
| Sepsis |
16.5% |
| Septic Shock |
9.2% |
| Thrombocytopenia |
7.3% |
| Venoocclusive Liver Disease |
6.7% |
| Pneumonia |
5.4% |
| Weight Increased |
4.8% |
| Platelet Count Decreased |
4.4% |
| Stomatitis |
4.1% |
| Pyrexia |
3.2% |
| Device Related Infection |
2.9% |
| Multi-organ Failure |
2.2% |
| Vomiting |
1.9% |
| Febrile Neutropenia |
1.6% |
| Hypokalaemia |
1.6% |
| Pancytopenia |
1.6% |
| Renal Failure |
1.6% |
| Tumour Lysis Syndrome |
1.6% |
| Cardiac Arrest |
1.3% |
| Cardiac Failure Congestive |
1.3% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
24.8% |
| Acute Lymphocytic Leukaemia |
20.1% |
| Prophylaxis |
15.7% |
| Drug Use For Unknown Indication |
7.9% |
| Prophylaxis Against Graft Versus Host Disease |
5.7% |
| Neutropenia |
5.0% |
| Pyrexia |
3.8% |
| Hypertension |
3.1% |
| Liver Disorder |
2.5% |
| Stem Cell Transplant |
2.5% |
| Acute Myeloid Leukaemia Recurrent |
2.2% |
| Pneumonia Fungal |
1.3% |
| Allogenic Bone Marrow Transplantation Therapy |
0.9% |
| Chronic Myeloid Leukaemia |
0.9% |
| Iron Overload |
0.6% |
| Leukaemia |
0.6% |
| Oral Herpes |
0.6% |
| Product Used For Unknown Indication |
0.6% |
| Renal Impairment |
0.6% |
| Acute Leukaemia |
0.3% |
|
| Multi-organ Failure |
18.6% |
| Vomiting |
11.6% |
| Loss Of Consciousness |
9.3% |
| Acute Generalised Exanthematous Pustulosis |
7.0% |
| Thrombocytopenia |
7.0% |
| Neutropenia |
4.7% |
| Pericardial Effusion |
4.7% |
| Septic Shock |
4.7% |
| Sudden Death |
4.7% |
| Vaginal Discharge |
4.7% |
| Acute Myeloid Leukaemia |
2.3% |
| Cardiac Failure |
2.3% |
| Coagulopathy |
2.3% |
| Drug Eruption |
2.3% |
| Lung Disorder |
2.3% |
| Lung Infiltration |
2.3% |
| Mucosal Inflammation |
2.3% |
| Off Label Use |
2.3% |
| Pain |
2.3% |
| Pancytopenia |
2.3% |
|
| Interacting |
| Acute Myeloid Leukaemia |
50.0% |
| Product Used For Unknown Indication |
33.3% |
| Drug Use For Unknown Indication |
16.7% |
|
| Thrombocytopenia |
66.7% |
| Respiratory Distress |
16.7% |
| Tachycardia |
16.7% |
|
